Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

The U.S. weight loss drug giant reported quarterly revenue of $17.60 billion, up 54% year over year, beating the consensus of $16.02 billion. This growth was driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices.

The company reported an adjusted earnings per share of $7.02, a sharp jump from $1.18 a year ago, beating the consensus of $5.70.

Analyst Take

Goldman Sachs on Friday wrote, "Headed into 2026, we continue to see LLY as optimally positioned into the launch of orforglipron, which represents one of the most significant new product cycles across our entire biopharma coverage."

Asad Haider maintains a Buy rating and raised the price forecast from $879 ...